70261-82-4

Basic information

• Product Name: 4-[(4-Methylpiperazin-1-yl)methyl]aniline
• Synonyms: 4-(4-METHYL-PIPERAZIN-1-YLMETHYL)-ANILINE;4-(4-METHYL-PIPERAZIN-1-YLMETHYL)-PHENYLAMINE;AKOS BB-8955;4-(4-Methylpiperazin-1-ylmethyl)phenylamine95%;4-(4-METHYLPIPERAZIN-1-YLMETHYL)PHENYLAMINE 95%;Benzenamine, 4-[(4-methyl-1-piperazinyl)methyl]-;1-methyl-4-(4-aminobenzyl)piperazine;FN1501
• CAS NO: 70261-82-4
• Molecular Formula: C₁₂H₁₉N₃
• Molecular Weight: 205.3
• EINECS: 200-158-5
• Mol File: 70261-82-4.mol
• Article Data: 30

Chemical Properties

• Boiling Point: 331.2 °C at 760 mmHg
• Flash Point: 152 °C
• Appearance: /
• Density: 1.085 g/cm³
• Vapor Pressure: 0.000158mmHg at 25°C
• Storage Temp.: 2-8°C(protect from light)
• Solubility: Chloroform (Slightly), Methanol (Slightly)
• PKA: 7.65±0.10(Predicted)
• CAS DataBase Reference: 4-[(4-Methylpiperazin-1-yl)methyl]aniline(CAS DataBase Reference)
• NIST Chemistry Reference: 4-[(4-Methylpiperazin-1-yl)methyl]aniline(70261-82-4)
• EPA Substance Registry System: 4-[(4-Methylpiperazin-1-yl)methyl]aniline(70261-82-4)

Safety Data

• Hazard Codes: Xi
• Statements: 36
• Safety Statements: 26
• HazardClass: IRRITANT
• Hazardous Substances Data: 70261-82-4(Hazardous Substances Data)

Usage

Uses

4-(4-Methylpiperazin-1-ylmethyl)phenylamine is an intermediate used to prepare aminopyridopyrimidinones as tyrosine kinase inhibitors and anticancer agents. It is also used in the synthesis of piperazinyltrifluoromethylphenylquinolinylbenzonaphthyridinone derivatives with anticancer activities.

InChI:InChI=1/C12H19N3/c1-14-6-8-15(9-7-14)10-11-2-4-12(13)5-3-11/h2-5H,6-10,13H2,1H3/p+2

Upstream product

• 70261-81-3 4-(4-nitrobenzyl)-1-methylpiperazine 
• 109-01-3 1-methyl-piperazine 
• 100-11-8 1-bromomethyl-4-nitro-benzene 
• 100-14-1 4-nitrobenzyl chloride 
• 555-16-8 4-nitrobenzaldehdye 
• 55121-99-8 (4-aminophenyl)(4-methylpiperazin-1-yl)methanone 
• 150-13-0 4-amino-benzoic acid 
• 99-99-0 1-methyl-4-nitrobenzene 

Downstream Products

• 80166-00-3 4-[(4-methylpiperazin-1-yl)methyl]phenol 
• 258876-65-2 [1-Biphenyl-4-yl-meth-(E)-ylidene]-[4-(4-methyl-piperazin-1-ylmethyl)-phenyl]-amine 
• 142335-66-8 2-[4-(4-Methyl-piperazin-1-ylmethyl)-phenoxy]-propionic acid ethyl ester 

Relevant articles and documents

(4 - Fused heterocycle-substituted amino)-3 - 1H-pyrazolecarboxamide compound and application thereof

The invention relates to the field of pharmaceutical chemistry and in particular relates to 4-(fused-heterocycle substituted amino)-1H-pyrazol-3-formamide compounds and application thereof, preparation methods of the compounds, pharmaceutical compositions

Discovery of 4-((7H-Pyrrolo[2,3-d]pyrimidin-4-yl)amino)-N-(4-((4-methylpiperazin-1-yl)methyl)phenyl)-1H-pyrazole-3-carboxamide (FN-1501), an FLT3- and CDK-Kinase Inhibitor with Potentially High Efficiency against Acute Myelocytic Leukemia

A series of 1-H-pyrazole-3-carboxamide derivatives have been designed and synthesized that exhibit excellent FLT3 and CDK inhibition and antiproliferative activities. A structure-activity-relationship study illustrates that the incorporation of a pyrimidine-fused heterocycle at position 4 of the pyrazole is critical for FLT3 and CDK inhibition. Compound 50 (FN-1501), which possesses potent inhibitory activities against FLT3, CDK2, CDK4, and CDK6 with IC50 values in the nanomolar range, shows antiproliferative activities against MV4-11 cells (IC50: 0.008 μM), which correlates with the suppression of retinoblastoma phosphorylation, FLT3, ERK, AKT, and STAT5 and the onset of apoptosis. Acute-toxicity studies in mice show that compound 50 (LD50: 186 mg/kg) is safer than AT7519 (32 mg/kg). In MV4-11 xenografts in a nude-mouse model, compound 50 can induce tumor regression at the dose of 15 mg/kg, which is more efficient than cytarabine (50 mg/kg). Taken together, these results demonstrate the potential of this unique compound for further development into a drug applied in acute-myeloid-leukemia (AML) therapeutics.

BICYCLIC UREA KINASE INHIBITORS AND USES THEREOF

The present disclosure provides compounds of Formula (I), (II), and (III). The provided compounds are able to bind protein kinases (e.g., SIK) and may be useful in modulating (e.g., inhibiting) the activity of a protein kinase (e.g., SIK, (e.g., SIK1, SIK2, or SIK3)) in a subject or cell. The provided compounds may be useful in treating or preventing a disease (e.g., proliferative disease, musculoskeletal disease, genetic disease, hematological disease, neurological disease, painful condition, psychiatric disorder, or metabolic disorder) in a subject in need thereof. Also provided are pharmaceutical compositions, kits, methods, and uses that include or involve a compound described herein.